The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).
 
Ian D. Davis
Research Funding - Astellas Pharma (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Martin R. Stockler
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bionomics (Inst); Celgene (Inst); Medivation (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Andrew James Martin
No Relationships to Disclose
 
Wendy Hague
Research Funding - Astellas Pharma (Inst)
 
Xanthi Coskinas
No Relationships to Disclose
 
Sonia Yip
No Relationships to Disclose
 
Emily Tu
No Relationships to Disclose
 
Nicola Jane Lawrence
Travel, Accommodations, Expenses - Roche
 
Howard Chan
No Relationships to Disclose
 
Ray McDermott
No Relationships to Disclose
 
Simon Chowdhury
No Relationships to Disclose
 
Vittorio Marchesin
Travel, Accommodations, Expenses - Astellas Pharma
 
Olwyn Deignan
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Francisco Vera-Badillo
No Relationships to Disclose
 
Scott A. North
Honoraria - Astellas Pharma; Janssen-Ortho; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; Novartis; Pfizer; Sanofi
 
Alexander Montenegro
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination